Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of … Read more
Crispr Therapeutics AG (CRSP) - Total Assets
Latest total assets as of December 2025: $2.27 Billion USD
Based on the latest financial reports, Crispr Therapeutics AG (CRSP) holds total assets worth $2.27 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Crispr Therapeutics AG - Total Assets Trend (2014–2025)
This chart illustrates how Crispr Therapeutics AG’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Crispr Therapeutics AG - Asset Composition Analysis
Current Asset Composition (December 2025)
Crispr Therapeutics AG's total assets of $2.27 Billion consist of 87.7% current assets and 12.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Crispr Therapeutics AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Crispr Therapeutics AG's current assets represent 87.7% of total assets in 2025, an increase from 63.4% in 2014.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2025, down from 61.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 33.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Crispr Therapeutics AG Competitors by Total Assets
Key competitors of Crispr Therapeutics AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Crispr Therapeutics AG - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Crispr Therapeutics AG generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Crispr Therapeutics AG is currently not profitable relative to its asset base.
Crispr Therapeutics AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.25 | 22.07 | 22.05 |
| Quick Ratio | 13.25 | 22.07 | 22.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.83 Billion | $ 1.85 Billion | $ 1.75 Billion |
Crispr Therapeutics AG - Advanced Valuation Insights
This section examines the relationship between Crispr Therapeutics AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.94 |
| Latest Market Cap to Assets Ratio | 2.11 |
| Asset Growth Rate (YoY) | 1.0% |
| Total Assets | $2.27 Billion |
| Market Capitalization | $4.79 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Crispr Therapeutics AG's assets at a significant premium ( 2.11x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Crispr Therapeutics AG's assets grew by 1.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Crispr Therapeutics AG (2014–2025)
The table below shows the annual total assets of Crispr Therapeutics AG from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.27 Billion | +1.04% |
| 2024-12-31 | $2.24 Billion | +0.56% |
| 2023-12-31 | $2.23 Billion | -0.60% |
| 2022-12-31 | $2.24 Billion | -18.49% |
| 2021-12-31 | $2.75 Billion | +50.54% |
| 2020-12-31 | $1.83 Billion | +71.36% |
| 2019-12-31 | $1.07 Billion | +118.14% |
| 2018-12-31 | $489.02 Million | +80.22% |
| 2017-12-31 | $271.35 Million | -21.34% |
| 2016-12-31 | $344.96 Million | +116.38% |
| 2015-12-31 | $159.42 Million | +10340.28% |
| 2014-12-31 | $1.53 Million | -- |